In theory, SGLT-2 inhibitors should be considered before GLP-1RA because of the reduction in both CV and total deaths associated with their use
However, due to constraints such as cost and availability in free clinics, some physicians have prescribed fixed-dose combinations, including metformin with DPP-4 inhibitors and GLP-1 RAs, anticipating potential benefits in HbA1c reduction and weight management
GLP-1 agonists like semaglutide have proven that harnessing this hormone alone can lead to significant weight loss (~15% on average)
But, it may be related to how semaglutide functions in your system
The practical conclusion it draws is that rebound is predictable in direction but not in magnitude for any single person
However, it may not be suitable for individuals with certain kidney conditions, which is why kidney function is typically monitored during treatment